

Vessel cooption in primary human tumors and metastases: does antiangiogenic treatment?

Cancer Medicine

2, 427-436

DOI: [10.1002/cam4.105](https://doi.org/10.1002/cam4.105)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Glioblastoma: A Pathogenic Crosstalk between Tumor Cells and Pericytes. PLoS ONE, 2014, 9, e101402.	1.1	99
2	Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer. International Journal of Molecular Sciences, 2014, 15, 23024-23041.	1.8	54
3	From Sprouting Angiogenesis to Erythrocytes Generation by Cancer Stem Cells: Evolving Concepts in Tumor Microcirculation. BioMed Research International, 2014, 2014, 1-8.	0.9	16
4	Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy?. International Journal of Molecular Sciences, 2014, 15, 5663-5679.	1.8	4
5	Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapy. FEBS Letters, 2014, 588, 1365-1371.	1.3	23
6	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis, 2014, 17, 471-494.	3.7	626
7	Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis. Cell, 2014, 156, 1002-1016.	13.5	672
8	Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts. International Journal of Cancer, 2014, 135, 295-307.	2.3	52
9	Angiotropism, Pericytic Mimicry and Extravascular Migratory Metastasis in Melanoma: An Alternative to Intravascular Cancer Dissemination. Cancer Microenvironment, 2014, 7, 139-152.	3.1	73
10	Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy. International Immunopharmacology, 2014, 22, 427-443.	1.7	74
11	Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. Cancer Journal (Sudbury, Mass), 2015, 21, 237-243.	1.0	90
12	A Hypothesis Concerning the Biphasic Dose-response of Tumors to Angiostatin and Endostatin. Dose-Response, 2015, 13, dose-response.1.	0.7	5
13	Neoplastic Non-Angiogenic Growth by Means of Vascular Co-Option. , 2015, 05, .		0
14	A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. Cancer Journal (Sudbury, Mass), 2015, 21, 274-283.	1.0	56
15	Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clinical and Experimental Metastasis, 2015, 32, 799-817.	1.7	16
16	Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Molecular Medicine, 2015, 7, 368-379.	3.3	136
17	Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. Journal of the National Cancer Institute, 2015, 107, .	3.0	97
18	Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy. Translational Oncology, 2015, 8, 176-184.	1.7	43

#	ARTICLE	IF	CITATIONS
19	Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 5488-5498.	3.2	24
20	Functional Characteristics of Brain Tumor Vascularization. , 2015, , 1075-1079.		4
21	Analysis of frequency of deep white matter metastasis on cerebral MRI. <i>Journal of Neuro-Oncology</i> , 2015, 123, 135-139.	1.4	9
22	The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy. <i>Pharmacological Reviews</i> , 2015, 67, 441-461.	7.1	190
23	New trends in guided nanotherapies for digestive cancers: A systematic review. <i>Journal of Controlled Release</i> , 2015, 209, 288-307.	4.8	87
24	The challenge of targeting metastasis. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 635-641.	2.7	147
25	Tie-1: A potential target for anti-angiogenesis therapy. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2015, 35, 615-622.	1.0	10
26	Multiple strategies of oxygen supply in <i>Drosophila</i> malignancies identify tracheogenesis as a novel cancer hallmark. <i>Scientific Reports</i> , 2015, 5, 9061.	1.6	41
27	Mechanism of tumour vascularization in experimental lung metastases. <i>Journal of Pathology</i> , 2015, 235, 384-396.	2.1	53
28	Next generation metronomic chemotherapy” report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€“8 May 2016, Mumbai. <i>Ecancermedalscience</i> , 2016, 10, 689.	0.6	10
29	Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer. <i>Oncotarget</i> , 2016, 7, 85437-85449.	0.8	26
30	Targeting Angiogenesis in Cancer Treatments: Where do we Stand?. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2016, 19, 226.	0.9	38
31	New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. <i>Drug Resistance Updates</i> , 2016, 29, 90-106.	6.5	190
32	Resistance to Targeted Therapies Against Adult Brain Cancers. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , .	0.1	4
33	Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome. <i>Scientific Reports</i> , 2016, 6, 19857.	1.6	13
34	In Vitro Assays for Endothelial Cell Functions Required for Angiogenesis: Proliferation, Motility, Tubular Differentiation, and Matrix Proteolysis. <i>Methods in Molecular Biology</i> , 2016, 1430, 121-147.	0.4	8
35	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw030.	3.0	144
36	Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw032.	3.0	11

#	ARTICLE	IF	CITATIONS
37	Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. <i>Cancer Research</i> , 2016, 76, 6988-7000.	0.4	45
38	Imaging oligometastatic cancer before local treatment. <i>Lancet Oncology</i> , The, 2016, 17, e406-e414.	5.1	22
39	White matter lesions reduce number of brain metastases in different cancers: a high-resolution MRI study. <i>Journal of Neuro-Oncology</i> , 2016, 130, 203-209.	1.4	9
41	Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. <i>Nature Medicine</i> , 2016, 22, 1294-1302.	15.2	342
42	Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways. <i>Scientific Reports</i> , 2016, 6, 23834.	1.6	80
43	Improving treatment of liver metastases by targeting nonangiogenic mechanisms. <i>Nature Medicine</i> , 2016, 22, 1209-1210.	15.2	4
44	Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2016, 35, 97.	4.9	23
45	Future options of anti-angiogenic cancer therapy. <i>Chinese Journal of Cancer</i> , 2016, 35, 21.	4.9	42
46	Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. , 2016, 164, 204-225.		99
47	Targeting metastasis. <i>Nature Reviews Cancer</i> , 2016, 16, 201-218.	12.8	1,111
48	Autophagy, a double-edged sword in anti-angiogenesis therapy. <i>Medical Oncology</i> , 2016, 33, 10.	1.2	56
49	Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas: a Histologic Study. <i>Pathology and Oncology Research</i> , 2017, 23, 803-809.	0.9	6
50	Brain Metastasis. , 2017, , 317-333.		3
51	The potential clinical promise of "multimodality" metronomic chemotherapy revealed by preclinical studies of metastatic disease. <i>Cancer Letters</i> , 2017, 400, 293-304.	3.2	59
52	Quantifying tumour vascularity in non-luminal breast cancers. <i>Journal of Clinical Pathology</i> , 2017, 70, 766-774.	1.0	9
53	High expression of PDGFR- β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence. <i>Scientific Reports</i> , 2017, 7, 43378.	1.6	51
54	A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. <i>Cancer Cell</i> , 2017, 31, 469-471.	7.7	7
55	Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. <i>Cancer Cell</i> , 2017, 31, 471-473.	7.7	8

#	ARTICLE	IF	CITATIONS
56	Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. <i>Oncolmmunology</i> , 2017, 6, e1316437.	2.1	40
57	Implications of neurovascular uncoupling in functional magnetic resonance imaging (fMRI) of brain tumors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3475-3487.	2.4	77
58	Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis. <i>International Journal of Cancer</i> , 2017, 141, 1091-1109.	2.3	29
59	Common pitfalls in preclinical cancer target validation. <i>Nature Reviews Cancer</i> , 2017, 17, 441-450.	12.8	134
60	New knowledge of the mechanisms of sorafenib resistance in liver cancer. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 614-622.	2.8	475
61	Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making. <i>European Journal of Surgical Oncology</i> , 2017, 43, 875-883.	0.5	32
62	Hypoxia and HIF pathway in cancer and the placenta. <i>Placenta</i> , 2017, 56, 8-13.	0.7	86
63	Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?. <i>European Journal of Cancer</i> , 2017, 70, 143-145.	1.3	7
64	Cyclin-dependent kinase 5 controls vasculogenic mimicry formation in non-small cell lung cancer via the FAK-AKT signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2017, 492, 447-452.	1.0	20
65	Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics. <i>Molecular and Translational Medicine</i> , 2017, , 161-182.	0.4	0
66	Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions. <i>Molecular Medicine Reports</i> , 2017, 16, 4393-4402.	1.1	60
67	CD271 determines migratory properties of melanoma cells. <i>Scientific Reports</i> , 2017, 7, 9834.	1.6	35
68	Overcoming key biological barriers to cancer drug delivery and efficacy. <i>Journal of Controlled Release</i> , 2017, 267, 15-30.	4.8	92
69	Monocarboxylate transporter 1 is a key player in gliomaâ€œendothelial cell crosstalk. <i>Molecular Carcinogenesis</i> , 2017, 56, 2630-2642.	1.3	31
70	Multiâ€œparametric profiling of renal cell, colorectal, and ovarian cancer identifies tumourâ€œtypeâ€œspecific stroma phenotypes and a novel vascular biomarker. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 214-224.	1.3	8
71	Microvascular proliferation is associated with aggressive tumour features and reduced survival in lung adenocarcinoma. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 249-257.	1.3	13
72	Tumor angiogenesis revisited: Regulators and clinical implications. <i>Medicinal Research Reviews</i> , 2017, 37, 1231-1274.	5.0	138
73	The â€œinherent viceâ€œ in the anti-angiogenic theory may cause the highly metastatic cancer to spread more aggressively. <i>Scientific Reports</i> , 2017, 7, 2365.	1.6	6

#	ARTICLE	IF	CITATIONS
74	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. <i>Journal of Pathology</i> , 2017, 241, 362-374.	2.1	162
75	EACR-MRS conference on Seed and Soil: In Vivo Models of Metastasis. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 449-456.	1.7	1
76	Collateral Damage Intended—Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2355.	1.8	30
77	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 101.	1.8	65
78	The Pleiotropic Role of L1CAM in Tumor Vasculature. <i>International Journal of Molecular Sciences</i> , 2017, 18, 254.	1.8	18
79	Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 416.	2.2	67
80	ALK signaling cascade confers multiple advantages to glioblastoma cells through neovascularization and cell proliferation. <i>PLoS ONE</i> , 2017, 12, e0183516.	1.1	21
81	Dusp3 deletion in mice promotes experimental lung tumour metastasis in a macrophage dependent manner. <i>PLoS ONE</i> , 2017, 12, e0185786.	1.1	14
82	Tumors and Blood Vessel Interactions: A Changing Hallmark of Cancer. , 2017, , 504-504.		0
83	Non-angiogenic tumours and their influence on cancer biology. <i>Nature Reviews Cancer</i> , 2018, 18, 323-336.	12.8	113
84	Resistance to Inhibitors of Angiogenesis. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 211-236.	0.1	2
85	Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 184-192.	1.3	56
86	Redundant angiogenic signaling and tumor drug resistance. <i>Drug Resistance Updates</i> , 2018, 36, 47-76.	6.5	93
87	Mechanisms of Metastasis. , 2018, , 1-35.		0
89	Astrocyte elevated gene-1 is overexpressed in non-small-cell lung cancer and associated with increased tumour angiogenesis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 26, 395-401.	0.5	9
90	Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 563-587.	2.4	29
91	Elevated Intracranial Pressure and Hydrocephalus in Brain Tumor Patients. , 2018, , 193-202.		0
92	Targeting the perivascular niche in brain tumors. <i>Current Opinion in Oncology</i> , 2018, 30, 54-60.	1.1	36

#	ARTICLE	IF	CITATIONS
93	Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 102-108.	2.0	19
94	The role of tumor microenvironment in resistance to anti-angiogenic therapy. <i>F1000Research</i> , 2018, 7, 326.	0.8	47
95	Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1). <i>Scientific Reports</i> , 2018, 8, 14724.	1.6	19
96	Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance. <i>Australian Veterinary Journal</i> , 2018, 96, 371-378.	0.5	20
97	Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling. <i>World Neurosurgery</i> , 2018, 120, e380-e391.	0.7	23
98	The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. <i>Annals of Oncology</i> , 2018, 29, 2240-2246.	0.6	113
99	Tumor Microenvironment Targeted Nanotherapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1230.	1.6	113
100	Consensus guidelines for the use and interpretation of angiogenesis assays. <i>Angiogenesis</i> , 2018, 21, 425-532.	3.7	429
101	Pericytes in the Premetastatic Niche. <i>Cancer Research</i> , 2018, 78, 2779-2786.	0.4	66
102	Recent advances in understanding of blood-brain tumor barrier (BTB) permeability mechanisms that enable better detection and treatment of brain tumors. , 2018, , 673-688.		5
103	Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. <i>Nature Cell Biology</i> , 2018, 20, 966-978.	4.6	186
104	Antiangiogenic Effect of Flavonoids and Chalcones: An Update. <i>International Journal of Molecular Sciences</i> , 2018, 19, 27.	1.8	79
105	Tumor angiogenesis and anti-angiogenic gene therapy for cancer (Review). <i>Oncology Letters</i> , 2018, 16, 687-702.	0.8	160
106	Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. <i>Molecular Cancer</i> , 2018, 17, 55.	7.9	75
107	Insights into the role of IL-32 in cancer. <i>Seminars in Immunology</i> , 2018, 38, 24-32.	2.7	54
108	Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer. <i>Oncology Letters</i> , 2018, 15, 6752-6762.	0.8	10
109	Blockade of Lymphangiogenesis Shapes Tumor-Promoting Adipose Tissue Inflammation. <i>American Journal of Pathology</i> , 2019, 189, 2102-2114.	1.9	9
110	Angiogenesis - Vessels Recruitment by Tumor Cells. <i>Learning Materials in Biosciences</i> , 2019, , 141-157.	0.2	1

#	ARTICLE	IF	CITATIONS
111	Hypoxia-Dependent Angiogenesis and Lymphangiogenesis in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1136, 71-85.	0.8	54
112	Molecular and Cell Biology of Cancer. <i>Learning Materials in Biosciences</i> , 2019, , .	0.2	3
113	Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. <i>Frontiers in Neurology</i> , 2019, 10, 460.	1.1	47
114	Hypoxia and Cancer Metastasis. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	5
115	Probabilistic independent component analysis of dynamic susceptibility contrast perfusion MRI in metastatic brain tumors. <i>Cancer Imaging</i> , 2019, 19, 14.	1.2	7
116	Vascular white matter lesions negatively correlate with brain metastases in malignant melanoma—Results from a retrospective comparative analysis. <i>Clinical Neurology and Neurosurgery</i> , 2019, 180, 117-121.	0.6	1
117	Ex vivo Dynamics of Human Glioblastoma Cells in a Microvasculature-on-a-Chip System Correlates with Tumor Heterogeneity and Subtypes. <i>Advanced Science</i> , 2019, 6, 1801531.	5.6	69
118	Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression. <i>International Journal of Cancer</i> , 2019, 145, 2267-2281.	2.3	60
119	<i>Clinical Ophthalmic Oncology</i> . , 2019, , .		5
120	<i>Cancer Angiogenesis</i> . , 2019, , 49-70.		0
121	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 469-493.	12.5	285
122	Neuropilins in the Context of Tumor Vasculature. <i>International Journal of Molecular Sciences</i> , 2019, 20, 639.	1.8	58
123	Biological barriers to cancer drug delivery, efficacy and cancer models. , 2019, , 359-423.		1
124	Contribution of Angiogenesis to Inflammation and Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1399.	1.3	201
125	The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. <i>Cells</i> , 2019, 8, 1602.	1.8	24
126	The multifaceted role of mesenchymal stem cells in cancer. <i>Seminars in Cancer Biology</i> , 2020, 60, 225-237.	4.3	112
127	The Acidic Tumor Microenvironment as a Driver of Cancer. <i>Annual Review of Physiology</i> , 2020, 82, 103-126.	5.6	551
128	Vessel co-option in glioblastoma: emerging insights and opportunities. <i>Angiogenesis</i> , 2020, 23, 9-16.	3.7	100

#	ARTICLE	IF	CITATIONS
129	Vessel co-option and resistance to anti-angiogenic therapy. <i>Angiogenesis</i> , 2020, 23, 55-74.	3.7	77
130	Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study. <i>JGH Open</i> , 2020, 4, 477-483.	0.7	9
131	Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. <i>Current Opinion in Oncology</i> , 2020, 32, 44-53.	1.1	18
132	Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. <i>Scientific Reports</i> , 2020, 10, 16211.	1.6	12
133	Endothelial-Tumor Cell Interaction in Brain and CNS Malignancies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7371.	1.8	19
134	The Effect of Glioblastoma on Pericytes. <i>Current Tissue Microenvironment Reports</i> , 2020, 1, 171-181.	1.3	4
135	Vascular mimicry: Triggers, molecular interactions and in vivo models. <i>Advances in Cancer Research</i> , 2020, 148, 27-67.	1.9	47
136	Blood Supply of Early Lung Adenocarcinomas in Mice and the Tumor-supplying Vessel Relationship: A Micro-CT Angiography Study. <i>Cancer Prevention Research</i> , 2020, 13, 989-996.	0.7	7
137	Vascular co-option and vasculogenic mimicry mediate resistance to antiangiogenic strategies. <i>Cancer Reports</i> , 2022, 5, e1318.	0.6	24
138	Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment. <i>Advanced Science</i> , 2020, 7, 1902971.	5.6	95
139	Risk of Dyslipidemia Associated with VEGF/VEGFR Inhibitors: A Meta-Analysis. <i>Translational Oncology</i> , 2020, 13, 100779.	1.7	6
140	Cdc42-Dependent Transfer of mir301 from Breast Cancer-Derived Extracellular Vesicles Regulates the Matrix Modulating Ability of Astrocytes at the Blood-Brain Barrier. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3851.	1.8	22
141	Disseminated Melanoma Cells Transdifferentiate into Endothelial Cells in Intravascular Niches at Metastatic Sites. <i>Cell Reports</i> , 2020, 31, 107765.	2.9	26
142	Translational considerations in nanomedicine: The oncology perspective. <i>Advanced Drug Delivery Reviews</i> , 2020, 158, 140-157.	6.6	31
143	Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 221.	1.3	213
144	Vasculogenic mimicry in carcinogenesis and clinical applications. <i>Journal of Hematology and Oncology</i> , 2020, 13, 19.	6.9	139
145	Exploiting Cancer's Tactics to Make Cancer a Manageable Chronic Disease. <i>Cancers</i> , 2020, 12, 1649.	1.7	3
146	ACE2 promotes angiogenesis and may be a novel treatment target for tongue squamous cell carcinoma. <i>Oral Diseases</i> , 2020, 26, 876-884.	1.5	4

#	ARTICLE	IF	CITATIONS
147	Dual anti-vascular function of human fibulin-3 variant, a potential new drug discovery strategy for glioblastoma. <i>Cancer Science</i> , 2020, 111, 940-950.	1.7	6
148	Nonangiogenic tumor growth. , 2020, , 15-32.		1
149	Remodeling of Metastatic Vasculature Reduces Lung Colonization and Sensitizes Overt Metastases to Immunotherapy. <i>Cell Reports</i> , 2020, 30, 714-724.e5.	2.9	51
150	Spatial Characterization of Tumor Perfusion Properties from 3D DCE-US Perfusion Maps are Early Predictors of Cancer Treatment Response. <i>Scientific Reports</i> , 2020, 10, 6996.	1.6	9
151	Flavones and flavonols may have clinical potential as CK2 inhibitors in cancer therapy. <i>Medical Hypotheses</i> , 2020, 141, 109723.	0.8	23
152	Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy. <i>Journal of Pathology</i> , 2020, 251, 213-223.	2.1	36
153	Intussusceptive angiogenesis as a key therapeutic target for cancer therapy. <i>Life Sciences</i> , 2020, 252, 117670.	2.0	30
154	Angiogenesis and vessel co-option in a mathematical model of diffusive tumor growth: The role of chemotaxis. <i>Journal of Theoretical Biology</i> , 2021, 512, 110526.	0.8	1
155	Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model. <i>Seminars in Cancer Biology</i> , 2021, 71, 52-64.	4.3	30
156	The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 610903.	1.8	24
157	Pathogenetic Features and Current Management of Glioblastoma. <i>Cancers</i> , 2021, 13, 856.	1.7	29
158	Modulation of the Vascular-Immune Environment in Metastatic Cancer. <i>Cancers</i> , 2021, 13, 810.	1.7	12
159	Alternative Vascularization Mechanisms in Tumor Resistance to Therapy. <i>Cancers</i> , 2021, 13, 1912.	1.7	28
160	Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 612774.	1.8	21
161	Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway. <i>Journal of Natural Products</i> , 2021, 84, 1755-1762.	1.5	20
162	TFPI2 Promotes Perivascular Migration in an Angiotropism Model of Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 662434.	1.3	6
163	The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids. <i>PLoS ONE</i> , 2021, 16, e0253258.	1.1	8
164	Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases. <i>Communications Biology</i> , 2021, 4, 950.	2.0	26

#	ARTICLE	IF	CITATIONS
165	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04604.	0.2	4
166	Epigenetic Regulation of Angiogenesis in Development and Tumors Progression: Potential Implications for Cancer Treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 689962.	1.8	25
167	Ion Channels, Transporters, and Sensors Interact with the Acidic Tumor Microenvironment to Modify Cancer Progression. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2021, , 39-84.	0.9	8
168	Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer - A Structured Review with Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0132481.	1.1	11
169	Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue. <i>PLoS ONE</i> , 2016, 11, e0161496.	1.1	36
170	Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. <i>PLoS ONE</i> , 2017, 12, e0188116.	1.1	9
171	Synergistic antitumor effect of a β -secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 34996-35007.	0.8	22
172	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. <i>Oncotarget</i> , 2016, 7, 21247-21258.	0.8	86
173	Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?. <i>Oncotarget</i> , 2017, 8, 39795-39804.	0.8	38
174	Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis. <i>Oncotarget</i> , 2016, 7, 38306-38318.	0.8	20
175	Circulating Biomarkers for Tumor Angiogenesis: Where Are We?. <i>Current Medicinal Chemistry</i> , 2020, 27, 2361-2380.	1.2	5
176	The Angiogenic Chemokines Expression Profile of Myeloid Cell Lines Co-Cultured with Bone Marrow-Derived Mesenchymal Stem Cells. <i>Cell Journal</i> , 2018, 20, 19-24.	0.2	3
177	Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers. <i>World Journal of Gastroenterology</i> , 2018, 24, 2710-2721.	1.4	7
178	EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells. <i>ELife</i> , 2016, 5, .	2.8	87
179	Improved Immunotherapy Efficacy by Vascular Modulation. <i>Cancers</i> , 2021, 13, 5207.	1.7	12
180	The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 173-191.	2.7	8
181	Host-Tumor Interactions in Brain Cancer Metastasis Leading to Drug Resistance. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 237-253.	0.1	0
182	The Implication of Antiangiogenic Treatment of Malignancies on Human Metabolism. , 2017, , 1-12.		0

#	ARTICLE	IF	CITATIONS
183	Angiogenesis features in patients with melanoma with different BRAf status. Russian Journal of Skin and Venereal Diseases, 2017, 20, 4-9.	0.0	0
184	The Implication of Anti-angiogenic Treatment of Malignancies on Human Metabolism. , 2019, , 661-672.		0
185	Drosophila Cancer Modeling Using the Eye Imaginal Discs. , 2020, , 259-291.		2
186	Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice. Advanced Pharmaceutical Bulletin, 2021, 11, 385-392.	0.6	3
187	Revisiting the hallmarks of cancer. American Journal of Cancer Research, 2017, 7, 1016-1036.	1.4	292
188	Angiogenesis Status in Patients with Acute Myeloid Leukemia: From Diagnosis to Post-hematopoietic Stem Cell Transplantation. International Journal of Organ Transplantation Medicine, 2017, 8, 57-67.	0.5	7
189	Lactic acid, a driver of tumor-stroma interactions. International Immunopharmacology, 2022, 106, 108597.	1.7	14
190	Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers. Cancers, 2022, 14, 1122.	1.7	5
191	Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Frontiers in Pharmacology, 2022, 13, 838133.	1.6	39
192	Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 628-645.	0.8	6
193	A functional role of S100A4/non-muscle myosin IIA axis for pro-tumorigenic vascular functions in glioblastoma. Cell Communication and Signaling, 2022, 20, 46.	2.7	2
194	The Paracrine Effect of Hypoxic and Normoxic Cancer Secretion on the Proliferation of Brain Endothelial Cells (bEnd.3). Cells, 2022, 11, 1197.	1.8	0
195	The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis. Cancers, 2021, 13, 6206.	1.7	63
196	RNA delivery for cancer gene therapy. , 2022, , 375-424.		0
197	Physiological instability is linked to mortality in primary central nervous system lymphoma: A caseâ€“control <sc>fMRI</sc> study. Human Brain Mapping, 2022, 43, 4030-4044.	1.9	3
198	Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy. Frontiers in Oncology, 0, 12, .	1.3	4
199	Angiopoietin-1 Upregulates Cancer Cell Motility in Colorectal Cancer Liver Metastases through Actin-Related Protein 2/3. Cancers, 2022, 14, 2540.	1.7	8
202	Neuroimaging issues in assessing glioma response to brain tumour therapy. , 2022, , 809-819.		0

#	ARTICLE	IF	CITATIONS
203	A Nomogram Incorporating Tumor-Related Vessels for Differentiating Adenocarcinoma In Situ from Minimally Invasive and Invasive Adenocarcinoma Appearing as Subsolid Nodules. <i>Academic Radiology</i> , 2022, , .	1.3	0
204	Double Immunohistochemical Staining on Formalin-Fixed Paraffin-Embedded Tissue Samples to Study Vascular Co-option. <i>Methods in Molecular Biology</i> , 2023, , 101-116.	0.4	1
205	Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 1419-1428.	0.5	4
206	Target tumor microenvironment by innate T cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
207	The molecular mechanisms underlying neutrophil infiltration in vessel co-opting colorectal cancer liver metastases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
208	Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort. <i>European Radiology</i> , 2023, 33, 4475-4485.	2.3	3
209	Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
210	Histopathological Patterns of Progression and Vessel Co-option. , 2022, , 447-450.		0
211	Development of Tumor-Vasculature Interaction on Chip Mimicking Vessel Co-Option of Glioblastoma. <i>Biochip Journal</i> , 2023, 17, 77-84.	2.5	5
212	Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors. <i>Diagnostics</i> , 2022, 12, 3120.	1.3	2
213	Vascular adaptation to cancer beyond angiogenesis: The role of PTEN. <i>Microvascular Research</i> , 2023, 147, 104492.	1.1	1
214	Vascular Progenitor Cells: From Cancer to Tissue Repair. <i>Journal of Clinical Medicine</i> , 2023, 12, 2399.	1.0	4
215	The evolving landscape of PCSK9 inhibition in cancer. <i>European Journal of Pharmacology</i> , 2023, 949, 175721.	1.7	7
216	Tumor vasculature vs tumor cell targeting: Understanding the latest trends in using functional nanoparticles for cancer treatment. <i>OpenNano</i> , 2023, 11, 100136.	1.8	4
217	Overcoming chemoresistance in non-angiogenic colorectal cancer by metformin via inhibiting endothelial apoptosis and vascular immaturity. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 262-275.	2.4	1
218	The Journey of Cancer Cells to the Brain: Challenges and Opportunities. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3854.	1.8	3
219	A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases. <i>Biomedicines</i> , 2023, 11, 731.	1.4	1
220	Shaping the brain vasculature in development and disease in the single-cell era. <i>Nature Reviews Neuroscience</i> , 2023, 24, 271-298.	4.9	20

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------